Drug resistance to antibody-drug conjugates: mechanisms, challenges, and perspectives.

Cancer Biol Med · 2026 · PMC13326606 · PMID 41943470

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The KATE2 study showed a trend towards improved survival in the PD-L1-positive subgroup of breast cancer patients who progressed on trastuzumab plus taxane, with 1-year OS rates of 94.3% for T-DM1 plus atezolizumab versus 87.9% for T-DM1 alone.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.